4D Molecular Therapeutics, Inc. $FDMT Stock Holdings Increased by Renaissance Technologies LLC

Posted by George Bondi on Aug 6th, 2026

Renaissance Technologies LLC boosted its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) by 12.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 578,265 shares of the company’s stock after purchasing an additional 65,365 shares during the period. Renaissance Technologies LLC owned about 1.11% of 4D Molecular Therapeutics worth $5,384,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wexford Capital LP acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter valued at $41,000. Daiwa Securities Group Inc. increased its stake in shares of 4D Molecular Therapeutics by 3,362.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after acquiring an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in shares of 4D Molecular Therapeutics in the fourth quarter worth $77,000. Martingale Asset Management L P raised its holdings in shares of 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after acquiring an additional 1,303 shares in the last quarter. Finally, Gabelli Funds LLC purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth $90,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Insider Transactions at 4D Molecular Therapeutics

In other news, insider David Kirn sold 12,415 shares of the company’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $10.05, for a total transaction of $124,770.75. Following the completion of the sale, the insider owned 871,737 shares in the company, valued at approximately $8,760,956.85. This represents a 1.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares in the company, valued at approximately $103,404. This represents a 53.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 197,226 shares of company stock valued at $2,200,677 in the last ninety days. Insiders own 7.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on FDMT shares. B. Riley Financial began coverage on 4D Molecular Therapeutics in a research note on Friday, July 31st. They issued a “buy” rating and a $37.00 target price on the stock. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.67.

View Our Latest Report on FDMT

4D Molecular Therapeutics Trading Up 0.2%

FDMT stock opened at $10.28 on Thursday. The firm has a market cap of $537.44 million, a PE ratio of -4.00 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a 1 year low of $5.33 and a 1 year high of $14.00. The company has a fifty day simple moving average of $10.67 and a 200 day simple moving average of $9.71.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The business had revenue of $3.05 million for the quarter, compared to analyst estimates of $2.59 million. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

About 4D Molecular Therapeutics

(Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.